LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update
View original at globenewswire.comLIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update BOCA RATON, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
The continued growth of Liora Technologies Europe further strengthens LIXTE's ability to accelerate innovative cancer therapies, including proton therapy through the LIGHT System
60% confidenceFollowing a recent study confirming the favorable safety profile of LB-100 in combination with GSK's dostarlimab, LIXTE has expanded its ovarian cancer trial
60% confidenceBased on published preclinical data, LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer
60% confidenceLB-100 is well-tolerated in cancer patients at doses associated with anti-cancer activity
60% confidenceLIXTE is evaluating opportunities to expand strategically and grow its team through pursuit of complementary oncology assets to enhance the pipeline
60% confidenceLiora's LiGHT System is believed to provide significant advantages over currently available technologies for treating tumors with proton therapy
60% confidenceLB-100 has consistently shown synergy with today's chemotherapy and immunotherapy approaches for the treatment of cancer
60% confidenceA genetically acquired reduction in PP2A activity may increase responsiveness to immune checkpoint blockade in Ovarian Clear Cell Carcinoma, particularly in tumors harboring somatic PPP2R1A mutations resulting in loss of PP2A function
60% confidence